Pathogenic MicroRNA's in myeloid malignancies

Frontiers in Genetics

Volumn 5, Issue SEP, 2014, Pages

  Khalaj, Mona ^a   Tavakkoli, Montreh ^a   Stranahan, Alec W ^a   Park, Christopher Y ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 125A; MICRORNA 125B; MICRORNA 142; MICRORNA 146; MICRORNA 146A; MICRORNA 155; MICRORNA 29; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL RENEWAL; EPIGENETICS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; INNATE IMMUNITY; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; MYELOPOIESIS; MYELOPROLIFERATIVE DISORDER; NONHUMAN; ONCOGENE;

EID: 84949116167     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2014.00361     Document Type: Article

References (142)

1. Kondo, M., et al., Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu Rev Immunol, 2003. 21: p. 759-806.
2. Weissman, I. L., Stem cells: units of development units of regeneration, and units in evolution. Cell, 2000. 100(1): p. 157-68.
3. Zhang, J., et al., PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature, 2006. 441(7092): p. 518-22.
4. Ramalho-Santos, M., et al., "Stemness": transcriptional profiling of embryonic and adult stem cells. Science, 2002. 298(5593): p. 597-600.
5. Park, I. K., et al., Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature, 2003. 423(6937): p. 302-5.
6. Deneault, E., et al., A functional screen to identify novel effectors of hematopoietic stem cell activity. Cell, 2009. 137(2): p. 369-79.
7. Miyamoto, K., et al., Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell, 2007. 1(1): p. 101-12.
8. Ting, S. B., et al., Asymmetric segregation and self-renewal of hematopoietic stem and progenitor cells with endocytic Ap2a2. Blood, 2012. 119(11): p. 2510-22.
9. Aguilo, F., et al., Prdm16 is a physiologic regulator of hematopoietic stem cells. Blood, 2011. 117(19): p. 5057-66.
10. Hope, K. J., et al., An RNAi screen identifies Msi2 and Prox1 as having opposite roles in the regulation of hematopoietic stem cell activity. Cell Stem Cell, 2010. 7(1): p. 101-13.
11. Vasilatou, D., et al., The role of microRNAs in normal and malignant hematopoiesis. Eur J Haematol, 2010. 84(1): p. 1-16.
12. Kluiver, J., et al., Regulation of pri-microRNA BIC transcription and processing in Burkittlymphoma. Oncogene, 2007. 26(26): p. 3769-76.
13. Fazi, F., et al., A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell, 2005. 123(5): p. 819-31.
14. Felli, N., et al., MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci U S A, 2005. 102(50): p. 18081-6.
15. Cameron, J. E., et al., Epstein-Barr virus latent membrane protein 1 induces cellular MicroRNA miR-146a, a modulator of lymphocyte signaling pathways. J Virol, 2008. 82(4): p. 1946-58.
16. Chen, C. Z., et al., MicroRNAs modulate hematopoietic lineage differentiation. Science, 2004. 303(5654): p. 83-6.
17. Zhou, B., et al., miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc Natl Acad Sci U S A, 2007. 104(17): p. 7080-5.
18. Calin, G. A., et al., Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA, 2004. 101(9): p. 2999-3004.
19. Dixon-McIver, A., et al., Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. PLoS One, 2008. 3(5): p. e2141.
20. Garzon, R., et al., MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood, 2008. 111(6): p. 3183-9.
21. Jongen-Lavrencic, M., et al., MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood, 2008. 111(10): p. 5078-85.
22. Chung, S. S., W. Hu, and C. Y. Park, The Role of MicroRNAs in Hematopoietic Stem Cell and Leukemic Stem Cell Function. Ther Adv Hematol, 2011. 2(5): p. 317-34.
23. Havelange, V., R. Garzon, and C. M. Croce, MicroRNAs: new players in acute myeloid leukaemia. Br J Cancer, 2009. 101(5): p. 743-8.
24. Kluiver, J., et al., The role of microRNAs in normal hematopoiesis and hematopoietic malignancies. Leukemia, 2006. 20(11): p. 1931-6.
25. Ooi, A. G., et al., MicroRNA-125b expands hematopoietic stem cells and enriches for the lymphoid-balanced and lymphoid-biased subsets. Proc Natl Acad Sci USA, 2010. 107(50): p. 21505-10.
26. Gerrits, A., et al., Genetic screen identifies microRNA cluster 99b/let-7e/125a as a regulator of primitive hematopoietic cells. Blood, 2012. 119(2): p. 377-87.
27. O'Connell, R. M., et al., MicroRNAs enriched in hematopoietic stem cells differentially regulate long-term hematopoietic output. Proc Natl Acad Sci USA, 2010. 107(32): p. 14235-40.
28. Guo, S., et al., MicroRNA miR-125a controls hematopoietic stem cell number. Proc Natl Acad Sci USA, 2010. 107(32): p. 14229-34.
29. Shi, X. B., et al., An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci USA, 2007. 104(50): p. 19983-8.
30. Sonoki, T., et al., Insertion of microRNA-125b-1, a human homologue oflin-4, into a rearranged immunoglobulin heavy chain gene locus in a patient with precursor B-cell acute lymphoblastic leukemia. Leukemia, 2005. 19(11): p. 2009-10.
31. Bousquet, M., et al., Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med, 2008. 205(11): p. 2499-506.
32. Klusmann, J. H., et al., miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes Dev, 2010. 24(5): p. 478-90.
33. Bousquet, M., et al., MicroRNA-125b transforms myeloid cell lines by repressing multiple mRNA. Haematologica, 2012. 97(11): p. 1713-21.
34. Lin, K. Y., et al., miR-125b, a target of CDX2, regulates cell differentiation through repression of the core binding factor in hematopoietic malignancies. J Biol Chem, 2011. 286(44): p. 38253-63.
35. Lindsten, T., et al., The proapoptotic activities of Bax and Bak limit the size of the neural stem cell pool. J Neurosci, 2003. 23(35): p. 11112-9.
36. Lindsten, T., et al., The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell, 2000. 6(6): p. 1389-99.
37. Chaudhuri, A. A., et al., Oncomir miR-125b regulates hematopoiesis by targeting the gene Lin28A. Proc Natl Acad Sci USA, 2012. 109(11): p. 4233-8.
38. Bousquet, M., et al., MicroRNA miR-125b causes leukemia. Proc Natl Acad Sci USA, 2010. 107(50): p. 21558-63.
39. Enomoto, Y., et al., MicroRNA-125b-1 accelerates a C-terminal mutant of C/EBPalpha (C/EBPalpha-C(m))-induced myeloid leukemia. Int J Hematol, 2012. 96(3): p. 334-41.
40. Hasle, H., Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol, 2001. 2(7): p. 429-36.
41. Elmen, J., et al., Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res, 2005. 33(1): p. 439-47.
42. Ebert, M. S. and P. A. Sharp, MicroRNA sponges: progress and possibilities. RNA, 2010. 16(11): p. 2043-50.
43. Chu, S. H., et al., FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm. Cell Stem Cell, 2012. 11(3): p. 346-58.
44. Boldin, M. P., et al., miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med, 2011. 208(6): p. 1189-201.
45. Starczynowski, D. T., et al., MicroRNA-146a disrupts hematopoietic differentiation and survival. Exp Hematol, 2011. 39(2): p. 167-178 e4.
46. Yang, L., et al., miR-146a controls the resolution of Tcell responses in mice. J Exp Med, 2012. 209(9): p. 1655-70.
47. Ghani, S., et al., Macrophage development from HSCs requires PU. 1-coordinated microRNA expression. Blood, 2011. 118(8): p. 2275-84.
48. Jurkin, J., et al., miR-146a is differentially expressed by myeloid dendritic cell subsets and desensitizes cells to TLR2-dependent activation. J Immunol, 2010. 184(9): p. 4955-65.
49. Labbaye, C., et al., A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis. Nat Cell Biol, 2008. 10(7): p. 788-801.
50. Silverman, N. and T. Maniatis, NF-kappaB signaling pathways in mammalian and insect innate immunity. Genes Dev, 2001. 15(18): p. 2321-42.
51. Hayden, M. S. and S. Ghosh, Shared principles in NF-kappaB signaling. Cell, 2008. 132(3): p. 344-62.
52. Taganov, K. D., et al., NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA, 2006. 103(33): p. 12481-6.
53. Taganov, K. D., M. P. Boldin, and D. Baltimore, MicroRNAs and immunity: tiny players in a big field. Immunity, 2007. 26(2): p. 133-7.
54. Labbaye, C., et al., PLZF induces megakaryocytic development, activates Tpo receptor expression and interacts with GATA1 protein. Oncogene, 2002. 21(43): p. 6669-79.
55. Avecilla, S. T., et al., Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med, 2004. 10(1): p. 64-71.
56. Starczynowski, D. T., et al., Identification ofmiR-145 and miR-146a as mediators of the 5q-syndrome phenotype. Nat Med, 2010. 16(1): p. 49-58.
57. Opalinska, J. B., et al., MicroRNA expression in maturing murine megakaryocytes. Blood, 2010. 116(23): p. e128-38.
58. Arvey, A., et al., Target mRNA abundance dilutes microRNA and siRNA activity. Mol SystBiol, 2010. 6: p. 363.
59. Zhao, J. L., et al., MicroRNA-146a acts as a guardian of the quality and longevity of hematopoietic stem cells in mice. Elife, 2013. 2: p. e00537.
60. Nimer, S. D., Myelodysplastic syndromes. Blood, 2008. 111(10): p. 4841-51.
61. Bradley, J. R. and J. S. Pober, Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene, 2001. 20(44): p. 6482-91.
62. Zhao, J. L., et al., NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc Natl Acad Sci U S A, 2011. 108(22): p. 9184-9.
63. Etzrodt, M., et al., Regulation of monocyte functional heterogeneity by miR-146a and Relb. Cell Rep, 2012. 1(4): p. 317-24.
64. Yang, W. L., et al., The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science, 2009. 325(5944): p. 1134-8.
65. Lepelley, P., et al., Is apoptosis a massive process in myelodysplastic syndromes? Br J Haematol, 1996. 95(2): p. 368-71.
66. Kishimoto, T., Interleukin-6: from basic science to medicine--40years in immunology. Annu Rev Immunol, 2005. 23: p. 1-21.
67. Ebert, B. L., et al., Identification ofRPS14 as a 5q-syndrome gene by RNA interference screen. Nature, 2008. 451(7176): p. 335-9.
68. Tam, W., Identification and characterization of human BIC, a gene on chromosome 21 that encodes a noncoding RNA. Gene, 2001. 274(1-2): p. 157-67.
69. Tam, W., D. Ben-Yehuda, and W. S. Hayward, bic, a novel gene activated by proviral insertions in avian leukosis virus-induced lymphomas, is likely to function through its noncoding RNA. Mol Cell Biol, 1997. 17(3): p. 1490-502.
70. Tam, W. and J. E. Dahlberg, miR-155/BIC as an oncogenic microRNA. Genes Chromosomes Cancer, 2006. 45(2): p. 211-2.
71. van den Berg, A., et al., High expression of B-cell receptor inducible gene BIC in all subtypes of Hodgkin lymphoma. Genes Chromosomes Cancer, 2003. 37(1): p. 20-8.
72. Eis, P. S., et al., Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA, 2005. 102(10): p. 3627-32.
73. Kluiver, J., et al., BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol, 2005. 207(2): p. 243-9.
74. Lagos-Quintana, M., et al., Identification of tissue-specific microRNAs from mouse. Curr Biol, 2002. 12(9): p. 735-9.
75. Georgantas, R. W., 3rd, et al., CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci USA, 2007. 104(8): p. 2750-5.
76. O'Connell, R. M., et al., Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med, 2008. 205(3): p. 585-94.
77. Masaki, S., et al., Expression patterns of microRNAs 155 and 451 during normal human erythropoiesis. Biochem Biophys Res Commun, 2007. 364(3): p. 509-14.
78. Thai, T. H., et al., Regulation of the germinal center response by microRNA-155. Science, 2007. 316(5824): p. 604-8.
79. Fulci, V., et al., Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood, 2007. 109(11): p. 4944-51.
80. Haasch, D., et al., T cell activation induces a noncoding RNA transcript sensitive to inhibition by immunosuppressant drugs and encoded by the proto-oncogene, BIC. Cell Immunol, 2002. 217(1-2): p. 78-86.
81. O'Connell, R. M., et al., MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA, 2007. 104(5): p. 1604-9.
82. O'Connell, R. M., et al., Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci USA, 2009. 106(17): p. 7113-8.
83. Garzon, R., et al., Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A, 2008. 105(10): p. 3945-50.
84. Rodriguez, A., et al., Requirement of bic/microRNA-155 for normal immune function. Science, 2007. 316(5824): p. 608-11.
85. Luo, J. M., et al., Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia. Leukemia, 2003. 17(1): p. 1-8.
86. Ono, M., et al., Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB. Nature, 1996. 383(6597): p. 263-6.
87. Damen, J. E., et al., The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase. Proc Natl Acad Sci USA, 1996. 93(4): p. 1689-93.
88. Helgason, C. D., et al., A dual role for Src homology 2 domain-containing inositol-5-phosphatase (SHIP) in immunity: aberrant development and enhanced function of b lymphocytes in ship -/-mice. J Exp Med, 2000. 191(5): p. 781-94.
89. Leung, W. H., T. Tarasenko, and S. Bolland, Differential roles for the inositol phosphatase SHIP in the regulation of macrophages and lymphocytes. Immunol Res, 2009. 43(1-3): p. 243-51.
90. Kalesnikoff, J., et al., The role of SHIP in cytokine-induced signaling. Rev Physiol Biochem Pharmacol, 2003. 149: p. 87-103.
91. Gorgoni, B., et al., C/EBP beta gene inactivation causes both impaired and enhanced gene expression and inverse regulation ofIL-12 p40 and p35 mRNAs in macrophages. J Immunol, 2002. 168(8): p. 4055-62.
92. Takeshita, F., et al., Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther, 2010. 18(1): p. 181-7.
93. Worm, J., et al., Silencing of microRNA-155 in mice during acute inflammatory response leads to derepression of c/ebp Beta and down-regulation of G-CSF. Nucleic Acids Res, 2009. 37(17): p. 5784-92.
94. Hazen, A. L., et al., SHIP is required for a functional hematopoietic stem cell niche. Blood, 2009. 113(13): p. 2924-33.
95. Valeri, N., et al., Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci USA, 2010. 107(15): p. 6982-7.
96. Tili, E., et al., Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. Proc Natl Acad Sci USA, 2011. 108(12): p. 4908-13.
97. Mantovani, A., et al., Cancer-related inflammation. Nature, 2008. 454(7203): p. 436-44.
98. Cancer Genome Atlas Research, N., Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med, 2013. 368(22): p. 2059-74.
99. Gauwerky, C. E., et al., Activation of MYC in a masked t(8;17) translocation results in an aggressive B-cell leukemia. Proc Natl Acad Sci USA, 1989. 86(22): p. 8867-71.
100. Dou, L., et al., MicroRNA-142-3p inhibits cell proliferation in human acute lymphoblastic leukemia by targeting the MLL-AF4 oncogene. Mol Biol Rep, 2013. 40(12): p. 6811-9.
101. Wang, X. S., et al., MicroRNA-29a and microRNA-142-3p are regulators of myeloid differentiation and acute myeloid leukemia. Blood, 2012. 119(21): p. 4992-5004.
102. Wang, F., et al., miR-29a and miR-142-3p downregulation and diagnostic implication in human acute myeloid leukemia. Mol Biol Rep, 2012. 39(3): p. 2713-22.
103. Dahlhaus, M., et al., Expression and prognostic significance of hsa-miR-142-3p in acute leukemias. Neoplasma, 2013. 60(4): p. 432-8.
104. Hwang, H. W., E. A. Wentzel, and J. T. Mendell, A hexanucleotide element directs microRNA nuclear import. Science, 2007. 315(5808): p. 97-100.
105. Garzon, R., et al., MicroRNA 29b functions in acute myeloid leukemia. Blood, 2009. 114(26): p. 5331-41.
106. Delhommeau, F., et al., Mutation in TET2 in myeloid cancers. N Engl J Med, 2009. 360(22): p. 2289-301.
107. Langemeijer, S. M., et al., Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet, 2009. 41(7): p. 838-42.
108. Tefferi, A., et al., Frequent TET2 mutations in systemic mastocytosis: clinical KITD816V and FIP1L1-PDGFRA correlates. Leukemia, 2009. 23(5): p. 900-4.
109. Tefferi, A., et al., Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia, 2009. 23(7): p. 1343-5.
110. Tefferi, A., et al., TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia, 2009. 23(5): p. 905-11.
111. Patel, J. P., et al., Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med, 2012. 366(12): p. 1079-89.
112. Ko, M., et al., Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature, 2010. 468(7325): p. 839-43.
113. Mizuno, S., et al., Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood, 2001. 97(5): p. 1172-9.
114. Shih, A. H., et al., The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer, 2012. 12(9): p. 599-612.
115. Garzon, R., et al., MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood, 2009. 113(25): p. 6411-8.
116. Ito, S., et al., Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science, 2011. 333(6047): p. 1300-3.
117. He, Y. F., et al., Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science, 2011. 333(6047): p. 1303-7.
118. Cheng, J., et al., An extensive network of TET2-targeting MicroRNAs regulates malignant hematopoiesis. Cell Rep, 2013. 5(2): p. 471-81.
119. Gong, J. N., et al., The role, mechanism and potentially therapeutic application of microRNA-29 family in acute myeloid leukemia. Cell Death Differ, 2014. 21(1): p. 100-12.
120. Fujimoto, T., et al., Cdk6 blocks myeloid differentiation by interfering with Runx1 DNA binding and Runx1-C/EBPalpha interaction. EMBO J, 2007. 26(9): p. 2361-70.
121. Han, Y. C., et al., microRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia. J Exp Med, 2010. 207(3): p. 475-89.
122. Huang, X., et al., Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clin Cancer Res, 2013. 19(9): p. 2355-67.
123. Liu, S., et al., Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell, 2010. 17(4): p. 333-47.
124. Raaijmakers, M. H., et al., Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature, 2010. 464(7290): p. 852-7.
125. Obernosterer, G., et al., Post-transcriptional regulation ofmicroRNA expression. RNA, 2006. 12(7): p. 1161-7.
126. Saj, A. and E. C. Lai, Control ofmicroRNA biogenesis and transcription by cell signaling pathways. Curr Opin Genet Dev, 2011. 21(4): p. 504-10.
127. Thomson, J. M., et al., Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev, 2006. 20(16): p. 2202-7.
128. Winter, J., et al., Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol, 2009. 11(3): p. 228-34.
129. Iorio, M. V., et al., MicroRNA gene expression deregulation in human breast cancer. Cancer Res, 2005. 65(16): p. 7065-70.
130. Scott, G. K., et al., Coordinate suppression of ERBB2 and ERBB3 by enforced expression ofmicro-RNA miR-125a ormiR-125b. J Biol Chem, 2007. 282(2): p. 1479-86.
131. Lee, Y. S. and A. Dutta, The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev, 2007. 21(9): p. 1025-30.
132. Jan, M., et al., Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med, 2012. 4(149): p. 149ra118.
133. Carroll, A. P., G. J. Goodall, and B. Liu, Understanding principles of miRNA target recognition and function through integrated biological and bioinformatics approaches. Wiley Interdiscip Rev RNA, 2014. 5(3): p. 361-79.
134. Garzon, R., G. Marcucci, and C. M. Croce, Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov, 2010. 9(10): p. 775-89.
135. Trang, P., et al., Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther, 2011. 19(6): p. 1116-22.
136. Kota, J., et al., Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell, 2009. 137(6): p. 1005-17.
137. Li, Q. J., et al., miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell, 2007. 129(1): p. 147-61.
138. Croce, C. M., Oncogenes and cancer. N Engl J Med, 2008. 358(5): p. 502-11.
139. van Rooij, E. and S. Kauppinen, Development of microRNA therapeutics is coming of age. EMBO Mol Med, 2014. 6(7): p. 851-64.
140. Pramanik, D., et al., Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther, 2011. 10(8): p. 1470-80.
141. Ibrahim, A. F., et al., MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res, 2011. 71(15): p. 5214-24.
142. Ranganathan, P., et al., Regulation of acute graft-versus-host disease by microRNA-155. Blood, 2012. 119(20): p. 4786-97.